Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: Results from an extended follow-up

Clinical Microbiology and Infection

Volumn 19, Issue 12, 2013, Pages

  Gianotti, N ^a   Galli, L ^a   Salpietro, S ^a   Cernuschi, M ^a   Bossolasco, S ^a   Maillard, M ^a   Spagnuolo, V ^a   Canducci, F ^b   Clementi, M ^a,c   Lazzarin, A ^a,c   Castagna, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus type 1viral load; Kinetic PCR; Virological failure; Virological rebound

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VIREMIA; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1VIRAL LOAD; KINETIC PCR; VIROLOGICAL FAILURE; VIROLOGICAL REBOUND;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84888046307     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12266     Document Type: Article

References (12)

1. Gianotti N, Galli L, Racca S et al. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 2012; 67: 213-217.
2. Doyle T, Smith C, Vitiello P et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2012; 54: 724-732.
3. Maggiolo F, Callegaro A, Cologni G et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012; 60: 473-482.
4. Vo TT, Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197: 1685-1694.
5. Cicconi P, Cozzi-Lepri A, Castagna A et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med 2010; 11: 104-113.
6. + T cell response. J Infect Dis 2011; 203: 960-968.
7. Gandhi RT, Coombs RW, Chan ES et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59: 229-235.
8. Chege D, Kovacs C, la Porte C et al. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial. AIDS 2012; 26: 167-174.
9. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
10. Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-1397.
11. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
12. + T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antivir Ther 2010; 15: 165-175.